3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 1
1
Status
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
CNS
1
Conditions
Neoplasms
2
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Uterine Cervical Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Precancerous Conditions
1
Neuroblastoma
1
Neoplasms by Site
1
Lung Neoplasms
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
Genital Diseases
1
Female Urogenital Diseases and Pregnancy Complications
1
Interventions
pembrolizumab
91
Blood Specimen Collection
44
Cyclophosphamide
37
Nivolumab
36
Bevacizumab
36
Standard of Care
32
Carboplatin
31
Surveys and Questionnaires
29
Paclitaxel
28
atezolizumab
25
Exercise
25
Pemetrexed
24
Gemcitabine
24
Cisplatin
23
Fluorouracil
22
Radiotherapy
20
Leucovorin
20
Dexamethasone
20
Oxaliplatin
19
Docetaxel
19
Rituximab
16
Irinotecan
16
Cetuximab
16
dostarlimab
15
Drug Therapy
15
Doxorubicin
15
Biopsy
15
130-nm albumin-bound paclitaxel
15
Prednisone
14
Ipilimumab
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms
×
Pregnancy Tests
×
1 year
×
Clear all
NCT02780128
2026-03-10
NEPENTHE
Children's Hospital of Philadelphia
Phase 1
Terminated
66 enrolled
NCT06815939
2026-01-29
OPTICS
DL Analytics
Phase NA
Recruiting
10,000 enrolled